RPRX royaltypharma.com Earnings per share growth rate in current year

Royalty Pharma plc (RPRX) generates revenue by acquiring rights to future royalties from promising drugs, thereby eliminating development risks. The company is building a closed biopharmaceutical financing ecosystem, tying drug developers to its resources. The absence of marketing and R&D expenses provides a powerful lever for portfolio scaling. The year-over-year percentage change in earnings per share reflects the real income dynamics, with the current figure standing at 11.40.

Royalty Pharma PLC (RPRX) Earnings per share growth in current year: for the period 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for Royalty Pharma Investments (RPRX)

- current quotes and average value forecast:

Market Chart Royalty Pharma Investments|RPRX - Price Target Chart

- market capitalization data:

Market Value Royalty Pharma PLC|RPRX - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share Royalty Pharma|RPRX - Company Book Value|Market Value to Book Value royaltypharma.com|RPRX - Company Total Assets

- debt and solvency information:

- earnings and market multiples details:

RPRX - Net Profit|Projected Future Earnings Royalty Pharma plc|RPRX - Price to Earnings Ratio|Future Price to Earnings Royalty Pharma|RPRX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Royalty Pharma PLC|RPRX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Royalty Pharma|RPRX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months royaltypharma.com|RPRX - Earnings per share growth in current year|Net earnings per share change forecast for next year Royalty Pharma plc

- revenue and sales proceeds data:

RPRX - Revenue and Sales Volume|Company Future Revenue Royalty Pharma Corp|RPRX - P/S Multiple|Forward P/S Multiple Royalty Pharma plc

Basic company analysis:Royalty Pharma Investments (RPRX)

Stable earnings per share confirm the long-term resilience of Royalty Pharma plc (RPRX), where annual EPS variability reflects the balance between growing royalty revenues and debt service obligations. This metric measures the annual growth rate of net income, which, combined with an ESG approach to selecting ethical assets, allows for an assessment of capital management efficiency and drug accessibility.

Main competitors